Thermo Fisher inks CAR T deal with JW Therapeutics

By The Science Advisory Board staff writers

February 4, 2021 -- Thermo Fisher has signed a marketing agreement with Chinese firm JW Therapeutics to supply that company with its Gibco CTS Dynabeads CD3/CD28. The agreement will support the development and manufacturing of chimeric antigen receptor (CAR) T therapies in China.

The agreement includes the development and commercial manufacturing of JW Therapeutics' relmacabtagene autoleucel ("relma-cel"), an anti-CD19 CAR T therapy for B-cell lymphoma. China's National Medical Products Administration has accepted JW Therapeutics' new drug application for relma-cell.

Thermo Fisher's CTS Dynabeads are part of its cell therapy systems portfolio, which is designed to mitigate manufacturing workflow challenges that cell therapy developers may encounter, the company said. The combination of anti-CD3 and anti-CD28 antibodies on Dynabeads is intended for ex vivo isolation, activation, and expansion of human T cells.

Thermo Fisher introduces cell therapy workflow media
Thermo Fisher Scientific has launched a new medium of the first human T lymphocytes (T cells) specifically designed for allogeneic cell therapy workflows.
Thermo Fisher closes Henogen acquisition
Thermo Fisher Scientific has closed its acquisition of Groupe Novasep's Henogen, a viral vector manufacturing business in Belgium, for approximately 725 million...
Thermo Fisher subsidizes more sequencers for global coronavirus research
Thermo Fisher Scientific is expanding a global SARS-CoV-2 program that provides its next-generation sequencers at subsidized prices to help analyze new...
Thermo Fisher launches managed equipment plan
Thermo Fisher Scientific has launched a new subscription-based program called Managed Equipment Solutions that combines instrument and equipment sales...
Thermo Fisher acquires Phitonex
Thermo Fisher Scientific has completed its acquisition of Phitonex, a North Carolina-based company that has created a spectral dye platform for high-resolution...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter